Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10
Fourth quarter and fiscal year 2025 results to be reported December 1, 2025
Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10
Fourth quarter and fiscal year 2025 results to be reported December 1, 2025
The regulatory framework for Biopharmaceutics Classification System (BCS) class III drug products provides a pathway for streamlined biowaivers in drug development, eliminating the need for expensive...
Fentanyl analogs, as emerging new psychoactive substances (NPS), pose a global public health threat due to widespread abuse, high toxicity, and frequent overdose fatalities.
High-quality data is the foundation of every major AI advance
Drug-induced kidney injury remains a significant concern in pharmaceutical development, with traditional methods often falling short in predicting renal toxicity across diverse compounds and patient populations.
Tuberculosis (TB) remains a global health challenge due to long treatment durations, poor adherence, and growing drug resistance. Inhalable co-amorphous systems (COAMS) offer a promising strategy for targeted pulmonary delivery...
Quantitative Systems Toxicology (QST) Software for Predicting and Explaining Drug-Induced Liver Injury (DILI)
Enhancing Training to be a personalized, representative and interactive strategic asset
ADMET Predictor has been enhanced to accurately predict properties of beyond Rule-of-Five (bRo5) molecules, including macrocycles and PROTACs.
Acyclovir (ACV), an antiviral drug, belongs to the BCS class III drug with intermediate solubility and low permeability.
Orally administered weakly basic compounds like aripiprazole (ARI) can precipitate in the small intestine due to limited solubility at intestinal pH.
To support regulatory decision-making without animal testing, Next-Generation Risk Assessment (NGRA) frameworks leverage New Approach Methodologies (NAM).
Training is one of the most critical parts of study start-up and yet, we often treat it like a box to check rather than the foundation of trial quality.
Physiologically based pharmacokinetic (PBPK) models are commonly used in human drug discovery and development and human health risk assessment of environmental chemicals.
Accelerate your model development
Introducing DILIsym® 11, the latest evolution of the industry’s leading quantitative systems toxicology (QST) platform.
Our ACAT™ model has been trusted by scientists for years, and the highly anticipated update—ACATPlus—is here.
The challenges of modern medicinal chemistry increase with the complexity of the chemical compounds studied.
Hydroxyurea is widely used in the management of sickle cell anemia.